- Home
- FBRX vs RADX Comparison
FBRX vs RADX Comparison
Compare FBRX & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- RADX
- Stock Information
- Founded
- FBRX N/A
- RADX 2021
- Country
- FBRX United States
- RADX Australia
- Employees
- FBRX N/A
- RADX N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- RADX
- Sector
- FBRX Health Care
- RADX
- Exchange
- FBRX Nasdaq
- RADX NYSE
- Market Cap
- FBRX 35.3M
- RADX 31.8M
- IPO Year
- FBRX N/A
- RADX N/A
- Fundamental
- Price
- FBRX $6.80
- RADX $3.96
- Analyst Decision
- FBRX Strong Buy
- RADX Strong Buy
- Analyst Count
- FBRX 3
- RADX 2
- Target Price
- FBRX $80.50
- RADX $13.50
- AVG Volume (30 Days)
- FBRX 26.6K
- RADX 22.6K
- Earning Date
- FBRX 05-20-2025
- RADX 02-26-2025
- Dividend Yield
- FBRX N/A
- RADX N/A
- EPS Growth
- FBRX N/A
- RADX N/A
- EPS
- FBRX N/A
- RADX N/A
- Revenue
- FBRX N/A
- RADX $204,609.00
- Revenue This Year
- FBRX N/A
- RADX N/A
- Revenue Next Year
- FBRX N/A
- RADX N/A
- P/E Ratio
- FBRX N/A
- RADX N/A
- Revenue Growth
- FBRX N/A
- RADX N/A
- 52 Week Low
- FBRX $4.11
- RADX $3.50
- 52 Week High
- FBRX $28.68
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- FBRX 50.51
- RADX N/A
- Support Level
- FBRX $6.20
- RADX N/A
- Resistance Level
- FBRX $6.91
- RADX N/A
- Average True Range (ATR)
- FBRX 0.61
- RADX 0.00
- MACD
- FBRX 0.01
- RADX 0.00
- Stochastic Oscillator
- FBRX 52.63
- RADX 0.00
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.